- ICH GCP
- EU Clinical Trials Registry
Latest Trials
EudraCT Number: 2022-000365-41 | Sponsor Protocol Number: CNTO1959UCO3004 | Start Date: 2023-04-26 | |||||||||||
Sponsor Name: Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Mode... | |||||||||||||
Medical condition: Moderately to Severely Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing) CZ (Ongoing) HU (Ongoing) BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001793-36 | Sponsor Protocol Number: GTX-102-001 | Start Date: 2023-04-26 | ||||||
Sponsor Name: Ultragenyx Pharmaceutical Inc. | ||||||||
Full Title: A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS) | ||||||||
Medical condition: Angelman Syndrome | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: DE (Ongoing) ES (Ongoing) FR (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005099-21 | Sponsor Protocol Number: MER-XMT-1536-3 | Start Date: 2023-04-25 | |||||||||||
Sponsor Name: Mersana Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensiti... | |||||||||||||
Medical condition: Recurrent, Platinum-Sensitive Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) NO (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) IT (Ongoing) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003810-35 | Sponsor Protocol Number: BMX-04-001 | Start Date: 2023-04-25 | ||||||||||||||||
Sponsor Name: BiomX Ltd. | ||||||||||||||||||
Full Title: A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomon... | ||||||||||||||||||
Medical condition: Cystic fibrosis Chronic Pseudomonas Aeruginosa Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) CZ (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003408-33 | Sponsor Protocol Number: ESR-21-21536 | Start Date: 2023-04-25 | |||||||||||
Sponsor Name: TheraOp gGmbH | |||||||||||||
Full Title: PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC | |||||||||||||
Medical condition: Locally advanced, unresectable non-small-cell lung cancer (NSCLC) (Stage III) with a PD-L1-expression of ≥ 1% | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001314-19 | Sponsor Protocol Number: VO659-CT01 | Start Date: 2023-04-25 | ||||||||||||||||
Sponsor Name: VICO Therapeutics B.V. | ||||||||||||||||||
Full Title: A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with sp... | ||||||||||||||||||
Medical condition: spinocerebellar ataxia types 1, 3 and Huntington’s disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) IT (Ongoing) DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002214-17 | Sponsor Protocol Number: NL78220.029.21 | Start Date: 2023-04-24 | ||||||||||||||||
Sponsor Name: Amsterdam University Medical Centers | ||||||||||||||||||
Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial | ||||||||||||||||||
Medical condition: Recurrent colorectal liver metastases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001413-37 | Sponsor Protocol Number: BELI(E)VE-Trial | Start Date: 2023-04-24 | |||||||||||
Sponsor Name: University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) The BELI(E)VE-Trial | |||||||||||||
Medical condition: relapsed and refractory t(11;14) Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003063-10 | Sponsor Protocol Number: ARGX-113-2010 | Start Date: 2023-04-21 | |||||||||||
Sponsor Name: argenx BV | |||||||||||||
Full Title: An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | |||||||||||||
Medical condition: Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Ongoing) GR (Ongoing) HU (Ongoing) DE (Ongoing) ES (Ongoing) BG (Ongoing) IT (Ongoing) NL (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004155-13 | Sponsor Protocol Number: BMS_IM101-931 | Start Date: 2023-04-20 | |||||||||||
Sponsor Name: Universitätsklinikum Freiburg | |||||||||||||
Full Title: Study to investigate the restoring of an immunological balance during therapy with abatacept Abatacept restores immune system equilibrium (ARISE) | |||||||||||||
Medical condition: CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positiv... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |